On May 9, 2024, Knight Therapeutics announced that it had entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development Inc., a wholly owned subsidiary of Ironshore Therapeutics Inc.

The agreement grants Knight Therapeutics Inc. the rights to seek regulatory approval and commercialize JORNAY PM, an extended release formulation of methylphenidate, a stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Canada and Latin America.

Davies Ward Phillips & Vineberg LLP represented Knight Therapeutics with a team that included Hillel Rosen (Corporate/Life Sciences) and Sumeet Dang (IP/Privacy/Life Sciences).